Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome

Abstract:

The weight of current evidence supports the presence of the following factors related to hypothalamic-pituitary-adrenal (HPA) axis dysfunction in patients with chronic fatigue syndrome (CFS): mild hypocortisolism; attenuated diurnal variation of cortisol; enhanced negative feedback to the HPA axis; and blunted HPA axis responsiveness. Furthermore, HPA axis changes seem clinically relevant, as they are associated with worse symptoms and/or disability and with poorer outcomes to standard treatments for CFS.

Regarding etiology, women with CFS are more likely to have reduced cortisol levels. Studies published in the past 8 years provide further support for a multifactorial model in which several factors interact to moderate HPA axis changes. In particular, low activity levels, depression and early-life stress appear to reduce cortisol levels, whereas the use of psychotropic medication can increase cortisol. Addressing these factors-for example, with cognitive behavioral therapy-can increase cortisol levels and is probably the first-line approach for correcting HPA axis dysfunction at present, as steroid replacement is not recommended.

Given what is now a fairly consistent pattern of findings for the type of HPA axis changes found in CFS, we recommend that future work focuses on improving our understanding of the cause and relevance of these observed changes.

Comment in: Neuroendocrine correlates of childhood trauma in CFS. [Nat Rev Endocrinol. 2012]

 

Source: Papadopoulos AS, Cleare AJ. Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol. 2011 Sep 27;8(1):22-32. doi: 10.1038/nrendo.2011.153. https://www.ncbi.nlm.nih.gov/pubmed/21946893

 

An Etiological Model for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Abstract:

Kindling might represent a heuristic model for understanding the etiology of Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Kindling occurs when an organism is exposed repeatedly to an initially sub-threshold stimulus resulting in hypersensitivity and spontaneous seizure-like activity. Among patients with ME/CFS, chronically repeated low-intensity stimulation due to an infectious illness might cause kindling of the limbic-hypothalamic-pituitary axis. Kindling might also occur by high-intensity stimulation (e.g., brain trauma) of the limbic-hypothalamic-pituitary axis. Once this system is charged or kindled, it can sustain a high level of arousal with little or no external stimulus and eventually this could lead to hypocortisolism. Seizure activity may spread to adjacent structures of the limbic-hypothalamic-pituitary axis in the brain, which might be responsible for the varied symptoms that occur among patients with ME/CFS. In addition, kindling may also be responsible for high levels of oxidative stress, which has been found in patients with ME/CFS.

 

Source: Jason LA, Sorenson M, Porter N, Belkairous N. An Etiological Model for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Neurosci Med. 2011 Mar 1;2(1):14-27. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166239/ (Full article)

 

Increased HDAC in association with decreased plasma cortisol in older adults with chronic fatigue syndrome

Abstract:

Hypocortisolism is a frequent finding in individuals with chronic fatigue syndrome (CFS) with other research findings implying potential dysregulation of glucocorticoid signaling. Glucocorticoid signaling is under the influence of several pathways, several of which are of interest in the study of CFS. Oxidative stress and decreased antioxidant capacity are known to disrupt the hypothalamic-pituitary-adrenal (HPA) axis (Epel et al., 2004) and the presence of histone deacetylases (HDAC) could also impact glucocorticoid signaling.

The intent of this pilot study was to investigate the relationship among oxidative stress elements, select HDAC’s (2/3) and glucocorticoid receptor signaling in an elderly sample with CFS. Findings suggest increased histone deacetylase activity, lower total antioxidant power, in the context of decreased plasma cortisol and increased plasma dehydroepiandrosterone concomitant with decreased expression of the encoding gene for the glucocorticoid receptor. These findings support the presence of HPA axis dysregulation in elderly individuals with CFS.

Copyright © 2011 Elsevier Inc. All rights reserved.

 

Source: Jason L, Sorenson M, Sebally K, Alkazemi D, Lerch A, Porter N, Kubow S. Increased HDAC in association with decreased plasma cortisol in older adults with chronic fatigue syndrome. Brain Behav Immun. 2011 Nov;25(8):1544-7. doi: 10.1016/j.bbi.2011.04.007. Epub 2011 Apr 28. https://www.ncbi.nlm.nih.gov/pubmed/21549189

 

The HPA axis in the pathogenesis of chronic fatigue syndrome

Abstract:

Chronic fatigue syndrome (CFS) is a clinical syndrome characterized by profound disabling chronic fatigue associated with a wide array of other physical symptoms. Its etiology is currently unknown. Among the various hypotheses, considerable interest has been placed in the hypothalamus-pituitary-adrenal axis as a possible target of the pathogenesis of CFS. This article reviews the available scientific evidence about a role of hypothalamic-pituitary-adrenal axis in the pathogenesis of chronic fatigue syndrome.

 

Source: Ursini F, Succurro E, Grembiale A, Gagliardi DA, Arturi F. The HPA axis in the pathogenesis of chronic fatigue syndrome. Clin Ter. 2010;161(5):461-4. [Article in Italian] https://www.ncbi.nlm.nih.gov/pubmed/20949245

 

Chronic fatigue syndrome reflects loss of adaptability

In this issue, Van Oosterwijck et al. [1] report that physical exercise lowered pain thresholds and was associated with exacerbation of symptoms in patients with myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) whereas, on the other hand, postexercise activity levels did not significantly decrease. Based on these and similar findings in patients with CFS, we present a conceptual framework that might provide a better understanding of the key features and pathophysiological mechanisms of CFS, and thus improve its diagnosis and treatment.

CFS as a failure of allostasis?

Van Oosterwijck et al. [1] correctly note the frequent cooccurrence of a chronic ‘fatigue–pain’ symptom cluster, usually diagnosed as CFS and/or fibromyalgia. Recently, it has been proposed that this cluster should be classified under the unifying label of ‘central sensitivity syndromes’– a broad range of functional somatic disorders mainly characterized by common sensory abnormalities (i.e. widespread pain, hyperalgesia, allodynia and hypersensitivity to noise, bright light and certain chemical substances) [2].

However, ‘stress intolerance and pain hypersensitivity syndromes’ may be a more appropriate umbrella term for these syndromes because it reflects these patients’ inability to adequately adapt to all kinds of physical and mental stressors, including pathological pain processing [3]. Within the innovative neurobiological stress paradigm of ‘allostasis’– the need for stability through continuous change [4] – this general loss of adaptability may be understood as a failure of allostasis.

Although the mechanisms underlying this failure are still unclear, they may include complex and interrelated disturbances of different components of the stress system, (i.e. the hypothalamic–pituitary–adrenal (HPA) axis), the sympathetic nervous system and various neurotransmitters that modulate perceptual–cognitive and affective brain circuits, all of which operate in intimate connection with the immune system and central pain mechanisms [5].

We and others have hypothesized that the pathophysiology of CFS might include a ‘switch’ from HPA axis hyperfunction to hypofunction following a period of chronic physical and/or psychosocial stress in vulnerable persons resulting in inadequate cortisol reactivity which may in turn, via low glucocorticoid signalling, increase inflammatory activity [5]. This assumption is consistent with the relatively low basal cortisol levels and blunted diurnal cortisol rhythm frequently observed in CFS patients [5], but recent data suggest that a decrease in glucocorticoid receptor sensitivity might play a role as well [6].

Abnormal activation of innate immunity involves the release of pro-inflammatory cytokines that influence the brain and give rise to ‘sickness behaviour’. This evolutionary, physiological and behavioural reaction normally occurs during infection or severe injury and its purpose is to optimally fight bodily threats by reorganizing priorities, saving energy and promoting healing and recovery. Characteristic symptoms are profound lethargy, feelings of malaise, concentration difficulties, headache, mild fever, sensory hypersensitivity and generalized pain. In CFS patients, however, this ‘flu-like’ symptom complex may be typically provoked by any kind of stressor (e.g. physical effort, mental pressure, strong emotions) and lead to a motivational shift by urging the patient to withdraw from activities [7].

Yet, the situation may be more complex. Not only is there evidence for basal hyperfunction of the sympathetic nervous system in CFS [8] and fibromyalgia [9], but dysfunctional descending pain-inhibiting pathways [10] and various psychological mechanisms may also contribute to abnormal pain perception [11].

The data presented by Van Oosterwijck et al. [1] fit within the stress adaptability hypothesis, which includes immune-related central pain sensitization, and thus make a strong case for refining current diagnostic criteria of CFS [12] to incorporate – as a mandatory criterion –patients’ maladaptive postexertional response. Novel clinical diagnostic criteria have meanwhile been developed [13] but it remains to be seen whether these criteria will empirically prove to be appropriate in identifying the key features of the illness.

You can read the rest of this comment here: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2796.2010.02240.x/full

Comment on: Pain inhibition and postexertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome: an experimental study. [J Intern Med. 2010]

 

Source: Van Houdenhove B, Luyten P. Chronic fatigue syndrome reflects loss of adaptability. J Intern Med. 2010 Sep;268(3):249-51. doi: 10.1111/j.1365-2796.2010.02240.x. http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2796.2010.02240.x/full (Full article)

 

Neuroendocrine and immune contributors to fatigue

Abstract:

Central fatigue, a persistent and subjective sense of tiredness, generally correlates poorly with traditional markers of disease. It is frequently associated with psychosocial factors, such as depression, sleep disorder, anxiety, and coping style, which suggest that dysregulation of the body’s stress systems may serve as an underlying mechanism in the maintenance of chronic fatigue (CF).

This article addresses the endocrine, neural, and immune factors that contribute to fatigue and describes research regarding the role of these factors in chronic fatigue syndrome as a model for addressing the biology of CF. In general, hypoactivity of the hypothalamic-pituitary-adrenal axis, autonomic nervous system alterations characterized by sympathetic overactivity and low vagal tone, as well as immune abnormalities, may contribute to the expression of CF. Noninvasive methods for evaluating endocrine, neural, and immune function are also discussed.

Simultaneous evaluation of neuroendocrine and immune systems with noninvasive techniques will help elucidate the underlying interactions of these systems, their role in disease susceptibility, and progression of stress-related disorders.

Copyright (c) 2010 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.

 

Source: Silverman MN, Heim CM, Nater UM, Marques AH, Sternberg EM. Neuroendocrine and immune contributors to fatigue. PM R. 2010 May;2(5):338-46. doi: 10.1016/j.pmrj.2010.04.008. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933136/ (Full article)

 

Activity in the hypothalamo-hypophyseal-adrenocortical system on experimental induction of chronic fatigue syndrome

Abstract:

Changes in the activity of the hypothalamo-hypophyseal-adrenocortical system (HHACS) were studied in an experimental model of chronic fatigue syndrome induced by i.p. administration of synthetic doublestranded RNA (polyriboinosinic:polyribocytidylic acid, Poly I:C) at a dose of 3 mg/kg.

Functional changes in the different components of the HHACS were detected using standard tests with i.p. ACTH or hydrocortisone on the background of cold stress and injections of Poly I:C. Single doses of Poly I:C were followed by the development of impairments to HHACS function, with decreases in the ACTH sensitivity of adrenal cells and suppression of the negative feedback mechanism, resulting in significant decreases in corticosterone concentrations in standard tests with administration of ACTH and hydrocortisone.

 

Source: Fomicheva EE, Filatenkova TA, Rybakina EG. Activity in the hypothalamo-hypophyseal-adrenocortical system on experimental induction of chronic fatigue syndrome. Neurosci Behav Physiol. 2010 Mar;40(3):245-50. doi: 10.1007/s11055-010-9250-3. Epub 2010 Feb 10. https://www.ncbi.nlm.nih.gov/pubmed/20146018

 

Cellular and molecular mechanisms of interaction between the neuroendocrine and immune systems under chronic fatigue syndrome in experiment

Abstract:

One of the main mechanisms of chronic fatigue syndrome development involves disturbances of interaction between the immune and neuroendocrine systems. The adequate experimental model for the search of these mechanisms is induction of fatigue in animals via the single intraperitoneal administration of synthetic double-stranded RNA – Poly I : C.

Investigation of alterations in cytotoxic and proliferation activities of splenocytcs, the intensity of immunomodulatory cytokines signaling via the sphingomyelin pathways in membrane P2 fraction of the brain cortex, as well as the activity of hypothalamic-pituitary adrenal (HP A) axis in the dynamics of chronic fatigue syndrome in rats has performed. Inhibition of both cytotoxic and proliferative activities of splenocytes during the period of fatigue development has been shown. Priority data concerning the suppression of the activity of neutral sphingomyelinase (nSMase) – the key enzyme of the sphingomyelin cascade – in membranes ofthe cells from the brain cortex on the 3d day after Poly I : C administration to rats have been obtained.

It was found that Poly I : C injection to rats led to disturbed HPA axis functions which was manifested by decreased corticosterone concentration in standard functional assays with ACTH and hydrocortisone administration.

It is suggested that disturbances in interaction between the immune and neuroendocrine systems during development of chronic fatigue syndrome, including alterations in HPA axis activity, are realized both on the level of changes in the activity of immune-competent cells and immediately on membranes of the brain cells.

 

Source: Rybakina EG, Shanin SN, Fomicheva EE, Korneva EA. Cellular and molecular mechanisms of interaction between the neuroendocrine and immune systems under chronic fatigue syndrome in experiment. Ross Fiziol Zh Im I M Sechenova. 2009 Dec;95(12):1324-35. [Article in Russian] https://www.ncbi.nlm.nih.gov/pubmed/20141043

 

Activity of hypothalamic-pituitary-adrenal axis by induction of experimental chronic fatigue syndrome

Abstract:

Changes in the activity of hypothalamic-pituitary adrenal (HPA) axis were investigated in experimental model of chronic fatigue syndrome(CFS) induced by intraperitoneal administration of synthetic double-stranded RNA (polyriboinosinic: polyribocytidylic acid, Poly I : C) to rats in the dose of 3 mg/kg body weight. In order to reveal functional changes in different links of the HPA axis, standard probes with intraperitoneal administration of ACTH and hydrocortisone against the background of cold stress application and Poly I : C injections were performed. A single injection of Poly I : C led to disordered HPA axis functions which was manifested by decreased sensitivity of the cells in the adrenal gland in response to ACTH, and suppression of the mechanism of negative feedback resulting in significant fall of corticosterone concentration in standard assays with ACTH and hydrocortisone administration.

 

Source: Fomicheva EE, Filatenkova TA, Rybakina EG. Activity of hypothalamic-pituitary-adrenal axis by induction of experimental chronic fatigue syndrome. Ross Fiziol Zh Im I M Sechenova. 2009 Jan;95(1):11-8. [Article in Russian] https://www.ncbi.nlm.nih.gov/pubmed/19323439

 

Does hypothalamic-pituitary-adrenal axis hypofunction in chronic fatigue syndrome reflect a ‘crash’ in the stress system?

Abstract:

The etiopathogenesis of chronic fatigue syndrome (CFS) remains poorly understood. Although neuroendocrine disturbances – and hypothalamic-pituitary-adrenal (HPA) axis hypofunction in particular – have been found in a large proportion of CFS patients, it is not clear whether these disturbances are cause or consequence of the illness.

After a review of the available evidence we hypothesize that that HPA axis hypofunction in CFS, conceptualized within a system-biological perspective, primarily reflects a fundamental and persistent dysregulation of the neurobiological stress system. As a result, a disturbed balance between glucocorticoid and inflammatory signaling pathways may give rise to a pathological cytokine-induced sickness response that may be the final common pathway underlying central CFS symptoms, i.e. effort/stress intolerance and pain hypersensitivity.

This comprehensive hypothesis on HPA axis hypofunction in CFS may stimulate diagnostic refinement of the illness, inform treatment approaches and suggest directions for future research, particularly focusing on the neuroendocrine-immune interface and possible links between CFS, early and recent life stress, and depression.

 

Source: Van Houdenhove B, Van Den Eede F, Luyten P. Does hypothalamic-pituitary-adrenal axis hypofunction in chronic fatigue syndrome reflect a ‘crash’ in the stress system? Med Hypotheses. 2009 Jun;72(6):701-5. doi: 10.1016/j.mehy.2008.11.044. Epub 2009 Feb 23. https://www.ncbi.nlm.nih.gov/pubmed/19237251